Trastuzumab-Pt(II) conjugate has been loaded with approximately 6.4 mol of platinum drugs per mole of antibody, retaining a high and selective binding affinity for the HER2 protein and HER2-positive SK-BR-3 breast cancer cells. Here, ERBB2 is linked to breast cancer.